Peroxiredoxin 2 as a chemotherapy responsiveness biomarker candidate in osteosarcoma revealed by proteomics

Kazutaka Kikuta, Naobumi Tochigi, Shigeru Saito, Tadakazu Shimoda, Hideo Morioka, Yoshiaki Toyama, Ako Hosono, Yoshiyuki Suehara, Yasuo Beppu, Akira Kawai, Setsuo Hirohashi, Tadashi Kondo

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Purpose: We aimed to identify novel chemotherapy responsiveness biomarkers for osteosarcoma (OS) by investigating the global protein expression profile of 12 biopsy samples from OS patients. Experimental design: Six patients were classified as good responders and six as poor responders, according to the Huvos grading system. The protein expression profiles obtained by 2-D DIGE consisted of 2250 protein spots. Results: Among them, we identified 55 protein spots whose intensity was significantly different (Bonferroni adjusted p-valueo0.01) between the two patient groups. Mass spectrometric protein identification demonstrated that the 55 spots corresponded to 38 distinct gene products including peroxiredoxin 2 (PRDX 2). Use of a specific antibody against PRDX 2 confirmed the differential expression of PRDX 2 between good and poor responders, while PRDX 2 levels as measured by Western blotting correlated highly with their corresponding 2-D DIGE values. The predictive value of PRDX 2 expression was further confirmed by examining an additional four OS cases using Western blotting. Conclusions and clinical relevance: These results establish PRDX 2 as a candidate for chemotherapy responsiveness marker in OS. Measuring PRDX 2 in biopsy samples before treatment may contribute to more effective management of OS.

Original languageEnglish
Pages (from-to)560-567
Number of pages8
JournalProteomics - Clinical Applications
Volume4
Issue number5
DOIs
Publication statusPublished - 2010 May

Fingerprint

Peroxiredoxins
Chemotherapy
Biomarkers
Osteosarcoma
Proteomics
Drug Therapy
Biopsy
Proteins
Western Blotting
Design of experiments
Research Design
Genes
Antibodies

Keywords

  • 2-D DIGE
  • Chemotherapy
  • Osteosarcoma
  • Peroxiredoxin 2

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Peroxiredoxin 2 as a chemotherapy responsiveness biomarker candidate in osteosarcoma revealed by proteomics. / Kikuta, Kazutaka; Tochigi, Naobumi; Saito, Shigeru; Shimoda, Tadakazu; Morioka, Hideo; Toyama, Yoshiaki; Hosono, Ako; Suehara, Yoshiyuki; Beppu, Yasuo; Kawai, Akira; Hirohashi, Setsuo; Kondo, Tadashi.

In: Proteomics - Clinical Applications, Vol. 4, No. 5, 05.2010, p. 560-567.

Research output: Contribution to journalArticle

Kikuta, K, Tochigi, N, Saito, S, Shimoda, T, Morioka, H, Toyama, Y, Hosono, A, Suehara, Y, Beppu, Y, Kawai, A, Hirohashi, S & Kondo, T 2010, 'Peroxiredoxin 2 as a chemotherapy responsiveness biomarker candidate in osteosarcoma revealed by proteomics', Proteomics - Clinical Applications, vol. 4, no. 5, pp. 560-567. https://doi.org/10.1002/prca.200900172
Kikuta, Kazutaka ; Tochigi, Naobumi ; Saito, Shigeru ; Shimoda, Tadakazu ; Morioka, Hideo ; Toyama, Yoshiaki ; Hosono, Ako ; Suehara, Yoshiyuki ; Beppu, Yasuo ; Kawai, Akira ; Hirohashi, Setsuo ; Kondo, Tadashi. / Peroxiredoxin 2 as a chemotherapy responsiveness biomarker candidate in osteosarcoma revealed by proteomics. In: Proteomics - Clinical Applications. 2010 ; Vol. 4, No. 5. pp. 560-567.
@article{9b41981d24c14c3c88f48d21f5bd3601,
title = "Peroxiredoxin 2 as a chemotherapy responsiveness biomarker candidate in osteosarcoma revealed by proteomics",
abstract = "Purpose: We aimed to identify novel chemotherapy responsiveness biomarkers for osteosarcoma (OS) by investigating the global protein expression profile of 12 biopsy samples from OS patients. Experimental design: Six patients were classified as good responders and six as poor responders, according to the Huvos grading system. The protein expression profiles obtained by 2-D DIGE consisted of 2250 protein spots. Results: Among them, we identified 55 protein spots whose intensity was significantly different (Bonferroni adjusted p-valueo0.01) between the two patient groups. Mass spectrometric protein identification demonstrated that the 55 spots corresponded to 38 distinct gene products including peroxiredoxin 2 (PRDX 2). Use of a specific antibody against PRDX 2 confirmed the differential expression of PRDX 2 between good and poor responders, while PRDX 2 levels as measured by Western blotting correlated highly with their corresponding 2-D DIGE values. The predictive value of PRDX 2 expression was further confirmed by examining an additional four OS cases using Western blotting. Conclusions and clinical relevance: These results establish PRDX 2 as a candidate for chemotherapy responsiveness marker in OS. Measuring PRDX 2 in biopsy samples before treatment may contribute to more effective management of OS.",
keywords = "2-D DIGE, Chemotherapy, Osteosarcoma, Peroxiredoxin 2",
author = "Kazutaka Kikuta and Naobumi Tochigi and Shigeru Saito and Tadakazu Shimoda and Hideo Morioka and Yoshiaki Toyama and Ako Hosono and Yoshiyuki Suehara and Yasuo Beppu and Akira Kawai and Setsuo Hirohashi and Tadashi Kondo",
year = "2010",
month = "5",
doi = "10.1002/prca.200900172",
language = "English",
volume = "4",
pages = "560--567",
journal = "Proteomics - Clinical Applications",
issn = "1862-8346",
publisher = "Wiley-VCH Verlag",
number = "5",

}

TY - JOUR

T1 - Peroxiredoxin 2 as a chemotherapy responsiveness biomarker candidate in osteosarcoma revealed by proteomics

AU - Kikuta, Kazutaka

AU - Tochigi, Naobumi

AU - Saito, Shigeru

AU - Shimoda, Tadakazu

AU - Morioka, Hideo

AU - Toyama, Yoshiaki

AU - Hosono, Ako

AU - Suehara, Yoshiyuki

AU - Beppu, Yasuo

AU - Kawai, Akira

AU - Hirohashi, Setsuo

AU - Kondo, Tadashi

PY - 2010/5

Y1 - 2010/5

N2 - Purpose: We aimed to identify novel chemotherapy responsiveness biomarkers for osteosarcoma (OS) by investigating the global protein expression profile of 12 biopsy samples from OS patients. Experimental design: Six patients were classified as good responders and six as poor responders, according to the Huvos grading system. The protein expression profiles obtained by 2-D DIGE consisted of 2250 protein spots. Results: Among them, we identified 55 protein spots whose intensity was significantly different (Bonferroni adjusted p-valueo0.01) between the two patient groups. Mass spectrometric protein identification demonstrated that the 55 spots corresponded to 38 distinct gene products including peroxiredoxin 2 (PRDX 2). Use of a specific antibody against PRDX 2 confirmed the differential expression of PRDX 2 between good and poor responders, while PRDX 2 levels as measured by Western blotting correlated highly with their corresponding 2-D DIGE values. The predictive value of PRDX 2 expression was further confirmed by examining an additional four OS cases using Western blotting. Conclusions and clinical relevance: These results establish PRDX 2 as a candidate for chemotherapy responsiveness marker in OS. Measuring PRDX 2 in biopsy samples before treatment may contribute to more effective management of OS.

AB - Purpose: We aimed to identify novel chemotherapy responsiveness biomarkers for osteosarcoma (OS) by investigating the global protein expression profile of 12 biopsy samples from OS patients. Experimental design: Six patients were classified as good responders and six as poor responders, according to the Huvos grading system. The protein expression profiles obtained by 2-D DIGE consisted of 2250 protein spots. Results: Among them, we identified 55 protein spots whose intensity was significantly different (Bonferroni adjusted p-valueo0.01) between the two patient groups. Mass spectrometric protein identification demonstrated that the 55 spots corresponded to 38 distinct gene products including peroxiredoxin 2 (PRDX 2). Use of a specific antibody against PRDX 2 confirmed the differential expression of PRDX 2 between good and poor responders, while PRDX 2 levels as measured by Western blotting correlated highly with their corresponding 2-D DIGE values. The predictive value of PRDX 2 expression was further confirmed by examining an additional four OS cases using Western blotting. Conclusions and clinical relevance: These results establish PRDX 2 as a candidate for chemotherapy responsiveness marker in OS. Measuring PRDX 2 in biopsy samples before treatment may contribute to more effective management of OS.

KW - 2-D DIGE

KW - Chemotherapy

KW - Osteosarcoma

KW - Peroxiredoxin 2

UR - http://www.scopus.com/inward/record.url?scp=77953837479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953837479&partnerID=8YFLogxK

U2 - 10.1002/prca.200900172

DO - 10.1002/prca.200900172

M3 - Article

VL - 4

SP - 560

EP - 567

JO - Proteomics - Clinical Applications

JF - Proteomics - Clinical Applications

SN - 1862-8346

IS - 5

ER -